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Background: Lung cancer is increasingly understood as
a disease made up of genomically defined subtypes
requiring distinct treatment strategies. We hypothesize
that young age at diagnosis (< 40 years) is a clinical
characteristic associated with an increased chance for a
targetable genomic alteration (GA). Our study will pro-
spectively characterize the somatic and germline geno-
mics of young lung cancer.
Method: Accrual opened in July 2014. Patients (pts) are
eligible if diagnosed with bronchogenic lung cancer <age
40. The study website, allows for virtual consenting and
remote participation from anywhere in the world. We
defined 7 GA of interest based on the Lung Cancer Mu-
tation Consortium (LCMC) (EGFR, KRAS, HER2, BRAF,
ALK, ROS1, RET). We aim to show the prevalence of
targetable GA in our stage 4 adenocarcinoma (AC) pts
will be greater in our population compared to the LCMC,
with an increase from 35% to 50%; and an improvement
in use of targeted therapy from 22% to 40%. Study
subjects without a known genotype undergo genomic
profiling with the FoundationOne test.
Results: Preliminary results of 71 pts with stage 4 AC
show that 82% have either an ALK re-arrangement
n¼32 (45%), an EGFR activating mutation n¼17 (24%),
a ROS1 fusion n¼5 (7%), a RET fusion n¼2 (3%) or a
HER2 mutation n¼2 (3%). Other GA of interest in those
with AC includes TP53, ATM and BRCA2 mutations. 49%
of our accrual has come from web based consenting. The
majority of subjects have come from North America and
Europe; and we would like representation from Latin
America.
Conclusion: Thus far in our prospective series our re-
sults have far exceeded our statistical expectations, with
82% of our stage 4 AC pts having an actionable mutation.
We have defined a genomically enriched subtype of lungcancer and laid the groundwork for further studies of
germline and environmental lung cancer risk factors. We
are planning a large-scale Case Control study of the
Epidemiology of YLC. Web based consenting is a feasible
method of bringing research to the patient.
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Background: In KEYNOTE-010, pembrolizumab demo-
nstrated superior OS over docetaxel in patients with
PD-L1-expressing advanced NSCLC that progressed after
2 cycles of platinum-doublet chemotherapy (HR 0.54,
